719 CD122-directed interleukin-2 complexes and αPD-L1 differentially require innate and adaptive immunity to treat local and metastatic bladder cancer

by Tyler Curiel, Yilun Deng, Ryan Reyes, Aravind Kancharla, Myrna Garcia, Harshita Gupta, Deyi Zhang, Niannian Ji, Neelam Mukherjee, Karen Wheeler, Anand Kornepati, Robert Svatek
Published 2020-11-01

Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study

by Niannian Ji, Neelam Mukherjee, Tyler J Curiel, Ryan M Reyes, Jonathan Gelfond, Martin Javors, Joshua J. Meeks, David J McConkey, Zhen-Ju Shu, Chethan Ramamurthy, Ryan Dennett, Robert S Svatek
Published 2021-03-01

Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial

by Niannian Ji, Neelam Mukherjee, Edwin E. Morales, Maggie E. Tomasini, Vincent Hurez, Tyler J. Curiel, Getahun Abate, Dan F. Hoft, Xiang-Ru Zhao, Jon Gelfond, Sourindra Maiti, Laurence J.N. Cooper, Robert S. Svatek
Published 2019-08-01

CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation

by Yilun Deng, Aravind Kancharla, Myrna Garcia, Deyi Zhang, Niannian Ji, Neelam Mukherjee, Karen Wheeler, Tyler J Curiel, Robert S Svatek, Ryan Michael Reyes, Harshita B Gupta, Alvaro S Padron, Chenghao Zhang, Anand V R Kornepati, Onur Boyman, Jose R Conejo-Garcia
Published 2021-04-01